(3,4-Dimethyl-isoxazol-5-yl)-methyl-amine | 69511-41-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (3,4-Dimethyl-isoxazol-5-yl)-methyl-amine
• 英文别名: N,3,4-trimethyl-1,2-oxazol-5-amine
• CAS: 69511-41-7
• 化学式: C₆H₁₀N₂O
• mdl: MFCD19220270
• 分子量: 126.158
• InChiKey: FXJUPEYOOAXFPS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3,4-Dimethyl-isoxazol-5-yl)-methyl-amine 以 乙醚 为溶剂， 生成 2,3-Dimethyl-2H-azirine-2-carboxylic acid methylamide
  参考文献：
  名称：

  Donati, Donato; Ponticelli, Fabio, Gazzetta Chimica Italiana, 1982, vol. 112, # 7/8, p. 293 - 296

  摘要：

  DOI：

文献信息

• Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4)
  申请人：Aston Nicola Mary

  公开号：US20080280911A1

  公开（公告）日：2008-11-13

  There are provided according to the invention novel compounds of formula (I)

  根据本发明提供了式(I)的新化合物。
• Amide Compound
  申请人：Matsumoto Takahiro

  公开号：US20080312226A1

  公开（公告）日：2008-12-18

  There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I 0 ): R 1 —C—R 2 —R 3 —R 4 (I 0 ) wherein Z is oxygen or sulfur; R 1 is aryl which may be substituted, or a heterocyclic group which may be substituted; R 1a is a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; R 2 is piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; R 3 is a group formed by eliminating two hydrogen atoms from a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, which may be further substituted, —CO—, etc.; and R 4 is a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; or a salt thereof.

  提供了一种FAAH抑制剂和预防或治疗脑血管疾病或睡眠障碍的药物，其中预防或治疗剂包括化合物(I0)的一种：R1-C-R2-R3-R4(I0)，其中Z为氧或硫；R1为芳基，可以被取代，或者是可以被取代的杂环基；R1a为氢原子，可以被取代的碳氢基，羟基等；R2为可以被取代的哌啶-1,4-二基，或者可以被取代的哌嗪-1,4-二基；R3为从具有1到3个氮、氧和硫杂原子的5元芳香杂环基中消除两个氢原子形成的基团，可以进一步被取代，-CO-等；R4为可以被取代的碳氢基或者可以被取代的杂环基；或其盐。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
  申请人：KYOWA HAKKO KIRIN CO., LTD.

  公开号：US20150299214A1

  公开（公告）日：2015-10-22

  The present invention provides a heterocyclic compound represented by the following formula (I), wherein X A represents CH and the like, R 1 represents cycloalkyl optionally having substituent(s) and the like, L represents a bond and the like, Y A represents —NH— and the like, R 2 represents a hydrogen atom and the like, R 3A represents the following formula (R 3A -1) (wherein, R 3 represents hydroxy and the like) and the like, and R 4A represents the following formula (R 4A -1) (wherein, R 4 and R 5 are the same or different and each represents a hydrogen atom and the like) and the like, or a pharmaceutically acceptable salt thereof, which is useful as a prophylactic and/or therapeutic agent for skin diseases and the like, and the like.

  本发明提供一种杂环化合物，其化学式表示为（I），其中XA代表CH等，R1代表环烷基，可选地具有取代基等，L代表键等，YA代表—NH—等，R2代表氢原子等，R3A代表下式（R3A-1）（其中，R3代表羟基等）等，R4A代表下式（R4A-1）（其中，R4和R5相同或不同，且每个代表氢原子等）等，或其药学上可接受的盐，其作为预防和/或治疗皮肤疾病等的药物具有用途。
• AMIDE COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1813606A1

  公开（公告）日：2007-08-01

  There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I0): wherein Z is oxygen or sulfur; R1 is aryl which may be substituted, or a heterocyclic group which may be substituted; R1a is a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; R2 is piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; R3 is a group formed by eliminating two hydrogen atoms from a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, which may be further substituted, -CO-, etc.; and R4 is a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; or a salt thereof.

  本发明提供了一种 FAAH 抑制剂和一种用于脑血管疾病或睡眠障碍的预防或治疗剂。该预防或治疗剂包括式（I0）化合物： 其中 Z 是氧或硫；R1 是可被取代的芳基或可被取代的杂环基团；R1a 是氢原子、可被取代的烃基、羟基等。R2 是可被取代的哌啶-1,4-二基或可被取代的哌嗪-1,4-二基；R3 是通过从具有 1 至 3 个选自氮、氧和硫的杂原子的 5 元芳香杂环基团中消除两个氢原子而形成的基团，该基团可被进一步取代、-CO- 等；以及 R4 是可被取代的烃基或可被取代的杂环基；或其盐。
• AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS
  申请人：TANABE SEIYAKU CO., LTD.

  公开号：EP1219609B1

  公开（公告）日：2007-04-04